Hookipa Pharma (NASDAQ:HOOK) Stock Rating Lowered by Royal Bank of Canada

Hookipa Pharma (NASDAQ:HOOKGet Free Report) was downgraded by equities research analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a research report issued on Friday, MarketBeat Ratings reports. They presently have a $2.00 price objective on the stock, down from their previous price objective of $48.00. Royal Bank of Canada’s target price suggests a potential downside of 0.99% from the stock’s current price.

Separately, JMP Securities reduced their target price on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, November 21st.

View Our Latest Stock Analysis on Hookipa Pharma

Hookipa Pharma Price Performance

Shares of NASDAQ:HOOK opened at $2.02 on Friday. The firm has a market capitalization of $24.35 million, a PE ratio of -0.54 and a beta of 0.71. Hookipa Pharma has a 1 year low of $1.88 and a 1 year high of $11.30. The firm’s 50-day moving average is $3.06 and its two-hundred day moving average is $4.67.

Hedge Funds Weigh In On Hookipa Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its stake in Hookipa Pharma by 12.3% in the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after acquiring an additional 108,844 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Hookipa Pharma by 38.4% in the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares in the last quarter. Finally, Ikarian Capital LLC purchased a new stake in shares of Hookipa Pharma during the 3rd quarter worth $228,000. 63.88% of the stock is owned by institutional investors and hedge funds.

About Hookipa Pharma

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Featured Stories

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.